SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
Amneal Pharmaceuticals, Inc. (AMRX) trades at a trailing P/E of 55.1, forward P/E of 13.3. Trailing earnings yield is 1.81%, forward earnings yield 7.55%. PEG 0.04 (Peter Lynch undervalued ≤1.0). Graham Number is $0.31.
Criteria proven by this page:
- VALUE (54/100, Partial) — mixed signals — some valuation metrics are favorable while others are stretched.
- Forward P/E 13.3 (down from trailing 55.1) — analysts expect earnings to grow, which would improve the valuation.
- PEG Ratio 0.04 — below 1.0 suggests the stock is undervalued relative to its earnings growth rate (Peter Lynch criterion).
- Trailing Earnings Yield 1.81% — below bond yields — investors are paying a premium for expected growth rather than current earnings. Forward yield improves to 7.55% as earnings recover.
- Analyst consensus target $16.00 (+22% upside) — significant upside potential according to Wall Street analysts.
Overall SharesGrow Score: 53/100 with 2/7 criteria passed.
SharesGrow 7-Criteria Score
~
VALUE
54/100
Price-to-Earnings & upside
Proven by this page
~
HEALTH
50/100
Debt-to-Equity & liquidity
→ Health
Valuation Snapshot — AMRX
Valuation Multiples
P/E (TTM)55.1
Forward P/E13.3
PEG Ratio0.04
Forward PEG0.04
P/B Ratio-56.08
P/S Ratio1.32
EV/EBITDA10.6
Per Share Data
EPS (TTM)$0.23
Forward EPS (Est.)$0.99
Book Value / Share$0.02
Revenue / Share$9.63
FCF / Share$0.76
Yields & Fair Value
Earnings Yield1.81%
Forward Earnings Yield7.55%
Dividend Yield0.00%
Graham Number$0.31
SharesGrow IV$172.64 (+1215.9%)
Analyst Target$16.00 (+22%)
Historical Valuation
| Year |
P/E (TTM) |
PEG Ratio |
P/B Ratio |
P/S Ratio |
Dividend Yield |
| 2016 |
12.1 |
0.54 |
-13.52 |
2.46 |
8.01% |
| 2017 |
11.4 |
0.35 |
-4.96 |
1.85 |
19.62% |
| 2018 |
-10.1 |
0.05 |
1.92 |
1.04 |
10.63% |
| 2019 |
-1.8 |
-0.01 |
2.74 |
0.39 |
- |
| 2020 |
7.5 |
-0.07 |
2.25 |
0.34 |
- |
| 2021 |
67.1 |
-0.76 |
1.98 |
0.34 |
- |
| 2022 |
-2.3 |
0.00 |
1.01 |
0.14 |
- |
| 2023 |
-12.6 |
0.29 |
53.70 |
0.44 |
- |
| 2024 |
-20.9 |
1.00 |
-22.40 |
0.88 |
- |
| 2025 |
54.8 |
-0.34 |
-55.77 |
1.31 |
- |
P/E Ratio & Earnings Yield
Earnings Per Share (EPS) History
| Year |
EPS (Diluted) |
Revenue |
Net Income |
Net Margin |
| 2016 |
$1.81 |
$1.02B |
$207.38M |
20.4% |
| 2017 |
$1.46 |
$1.03B |
$167.65M |
16.2% |
| 2018 |
$-1.33 |
$1.66B |
$-169.73M |
-10.2% |
| 2019 |
$-4.57 |
$1.63B |
$-603.57M |
-37.1% |
| 2020 |
$0.61 |
$1.99B |
$91.06M |
4.6% |
| 2021 |
$0.07 |
$2.09B |
$10.62M |
0.5% |
| 2022 |
$-0.86 |
$2.21B |
$-129.99M |
-5.9% |
| 2023 |
$-0.48 |
$2.39B |
$-83.99M |
-3.5% |
| 2024 |
$-0.38 |
$2.79B |
$-116.89M |
-4.2% |
| 2025 |
$0.22 |
$3.02B |
$72.06M |
2.4% |
Analyst Estimates
| Year |
EPS (Avg) |
EPS Range |
Revenue (Avg) |
Revenue Range |
Analysts |
| 2026 |
$0.99 |
$0.98 – $1.00 |
$3.09B |
$3.07B – $3.1B |
3 |
| 2027 |
$1.18 |
$1.13 – $1.24 |
$3.3B |
$3.28B – $3.33B |
3 |
| 2028 |
$1.37 |
$1.36 – $1.39 |
$3.5B |
$3.5B – $3.5B |
1 |
